Drugs / JMKX001899
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06946927 | Jun 2025 → Feb 2026 overdue | non-small cell lung carcinoma | Jemincare | Recruiting | No outcome recorded |
| Phase 1 | NCT06473948 | Jul → Sep 2024 | cancer | Jemincare | Unknown | No outcome recorded |
| Phase 1 | NCT06348290 | Apr → May 2024 | cancer | Jemincare | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07242274 | Dec 2025 → Dec 2027 expected | non-small cell lung carcinoma | Jemincare | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JMKX001899 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07242274 ↗ |
| Action | Inhibit | “designed to selectively inhibit the KRAS G12C mutation” NCT07242274 ↗ |
| Route | Oral | “JMKX001899 was administered orally once daily after a standardized meal from Day 9 to Day 20 and Day 22.” NCT06348290 ↗ |
| Target | KRAS | “designed to selectively inhibit the KRAS G12C mutation” NCT07242274 ↗ |